Drug research

RP1

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Genetically modified herpes simplex type 1 virus

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)NCT03767348	Replimune, Inc.	Phase 2	Active not recruiting	2028-06Estimated
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin CancerNCT04050436	Replimune, Inc.	Phase 2	Active not recruiting	2025-09Estimated

Replimune, Inc.Active not recruitingPrimary completion: 2028-06 · Estimated

Trial details

Replimune, Inc.Active not recruitingPrimary completion: 2025-09 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.